Zhitong Finance App News, Anke Biotech (300009.SZ) issued an announcement. Recently, the clinical trial application for AK2405, an innovative drug independently developed by the company, was accepted by the State Drug Administration. AK2405 for injection is an antibody-conjugated drug (ADC) targeting HER2. Pre-clinical studies have confirmed that injectable AK2405 has high specificity and high antitumor activity. This product is registered and classified as a therapeutic biological product category 1: an innovative biological product. The proposed indication is advanced malignant solid tumors.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.